Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
One year into the COVID‐19 pandemic, the cumulative number of confirmed COVID‐19 cases in Norway was still low. In January 2021, when the Norwegian COVID‐19 vaccination campaign started, the national seroprevalence estimate of SARS‐CoV‐2 antibodies was 3.2%. We have conducted a nationwide cross‐sectional study in August 2021 to invest...
Alternative Titles
Full title
Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349429
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349429
Other Identifiers
ISSN
1750-2640,1750-2659
E-ISSN
1750-2659
DOI
10.1111/irv.13024
